Neuroendocrine neoplasms of the breast: a review of literature.

IF 3.4 3区医学 Q1 PATHOLOGY Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2024-07-09 DOI:10.1007/s00428-024-03856-y

Federica Vegni, Ilenia Sara De Stefano, Federica Policardo, Pietro Tralongo, Angela Feraco, Angela Carlino, Giulia Ferraro, Qianqian Zhang, Giulia Scaglione, Nicoletta D'Alessandris, Elena Navarra, Gianfranco Zannoni, Angela Santoro, Antonino Mule, Esther Diana Rossi

{"title":"Neuroendocrine neoplasms of the breast: a review of literature.","authors":"Federica Vegni, Ilenia Sara De Stefano, Federica Policardo, Pietro Tralongo, Angela Feraco, Angela Carlino, Giulia Ferraro, Qianqian Zhang, Giulia Scaglione, Nicoletta D'Alessandris, Elena Navarra, Gianfranco Zannoni, Angela Santoro, Antonino Mule, Esther Diana Rossi","doi":"10.1007/s00428-024-03856-y","DOIUrl":null,"url":null,"abstract":"<p><p>Primary neuroendocrine neoplasms (NENs) of the breast are characterized by neuroendocrine architectural and cytological features, which must be supported by immunohistochemical positivity for neuroendocrine markers (such as Chromogranin and Synaptophysin). According to the literature, making a diagnosis of primary neuroendocrine breast cancer always needs to rule out a possible primary neuroendocrine neoplasm from another site. Currently, the latest 2022 version of the WHO of endocrine and neuroendocrine neoplasms has classified breast NENs as well-differentiated neuroendocrine tumours (NETs) and aggressive neuroendocrine carcinomas (NECs), differentiating them from invasive breast cancers of no special type (IBCs-NST). with neuroendocrine features. The current review article describes six cases from our series and a comprehensive review of the literature in the field of NENs of the breast.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329594/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-024-03856-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Primary neuroendocrine neoplasms (NENs) of the breast are characterized by neuroendocrine architectural and cytological features, which must be supported by immunohistochemical positivity for neuroendocrine markers (such as Chromogranin and Synaptophysin). According to the literature, making a diagnosis of primary neuroendocrine breast cancer always needs to rule out a possible primary neuroendocrine neoplasm from another site. Currently, the latest 2022 version of the WHO of endocrine and neuroendocrine neoplasms has classified breast NENs as well-differentiated neuroendocrine tumours (NETs) and aggressive neuroendocrine carcinomas (NECs), differentiating them from invasive breast cancers of no special type (IBCs-NST). with neuroendocrine features. The current review article describes six cases from our series and a comprehensive review of the literature in the field of NENs of the breast.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

乳腺神经内分泌肿瘤：文献综述。

乳腺原发性神经内分泌肿瘤（NENs）具有神经内分泌结构和细胞学特征，必须辅以神经内分泌标志物（如嗜铬粒蛋白（Chromogranin）和突触素（Synaptophysin））免疫组化阳性。根据文献，诊断原发性神经内分泌乳腺癌时，必须排除可能来自其他部位的原发性神经内分泌肿瘤。目前，世界卫生组织（WHO）关于内分泌和神经内分泌肿瘤的最新 2022 年版本将乳腺神经内分泌肿瘤分为分化良好的神经内分泌肿瘤（NET）和侵袭性神经内分泌癌（NEC），将其与无特殊类型的浸润性乳腺癌（IBCs-NST）区分开来。本综述文章介绍了我们系列中的六个病例，并对乳腺神经内分泌瘤领域的文献进行了全面回顾。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Virchows Archiv 医学-病理学

CiteScore

7.40

自引率

2.90%

发文量

204

审稿时长

4-8 weeks

期刊介绍： Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.